M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures

G Musumeci, I Bon, D Lembo, V Cagno, MC Re, C Signoretto, E Diani, L Lopalco, C Pastori, L Martin, G Ponchel, D Gibellini, K Bouchemal

Research output: Contribution to journalArticle

Abstract

Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1) transmission and disease. In this report, we first analyzed the antiviral activity of the miniCD4 M48U1 peptide formulated in hydroxyethylcellulose (HEC) hydrogel in activated peripheral blood mononuclear cells (PBMCs) infected with R5-and X4-Tropic HIV-1 strains. The results demonstrate that M48U1 prevented infection by several HIV-1 strains including laboratory strains, and HIV-1 subtype B and C strains isolated from the activated PBMCs of patients. M48U1 also inhibited infection by two HIV-1 transmitted/founder infectious molecular clones (pREJO.c/2864 and pTHRO.c/2626). In addition, M48U1 was administered in association with tenofovir, and these two antiretroviral drugs synergistically inhibited HIV-1 infection. In the next series of experiments, we tested M48U1 alone or in combination with tenofovir in HEC hydrogel with an organ-like structure mimicking human cervicovaginal tissue. We demonstrated a strong antiviral effect in absence of significant tissue toxicity. Together, these results indicate that co-Treatment with M48U1 plus tenofovir is an effective antiviral strategy that may be used as a new topical microbicide to prevent HIV-1 transmission. © 2017 The Author(s).
Original languageEnglish
Article number41018
JournalScientific Reports
Volume7
Issue number10
DOIs
Publication statusPublished - 2017

Fingerprint

Tenofovir
HIV Infections
HIV-1
Blood Cells
Antiviral Agents
Hydrogel
Local Anti-Infective Agents
Anti-Infective Agents
Infection

Cite this

M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. / Musumeci, G; Bon, I; Lembo, D; Cagno, V; Re, MC; Signoretto, C; Diani, E; Lopalco, L; Pastori, C; Martin, L; Ponchel, G; Gibellini, D; Bouchemal, K.

In: Scientific Reports, Vol. 7, No. 10, 41018, 2017.

Research output: Contribution to journalArticle

Musumeci, G, Bon, I, Lembo, D, Cagno, V, Re, MC, Signoretto, C, Diani, E, Lopalco, L, Pastori, C, Martin, L, Ponchel, G, Gibellini, D & Bouchemal, K 2017, 'M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures', Scientific Reports, vol. 7, no. 10, 41018. https://doi.org/10.1038/srep41018
Musumeci, G ; Bon, I ; Lembo, D ; Cagno, V ; Re, MC ; Signoretto, C ; Diani, E ; Lopalco, L ; Pastori, C ; Martin, L ; Ponchel, G ; Gibellini, D ; Bouchemal, K. / M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. In: Scientific Reports. 2017 ; Vol. 7, No. 10.
@article{3e9fa6ff4ee44394a9f5d047cdd2b639,
title = "M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures",
abstract = "Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1) transmission and disease. In this report, we first analyzed the antiviral activity of the miniCD4 M48U1 peptide formulated in hydroxyethylcellulose (HEC) hydrogel in activated peripheral blood mononuclear cells (PBMCs) infected with R5-and X4-Tropic HIV-1 strains. The results demonstrate that M48U1 prevented infection by several HIV-1 strains including laboratory strains, and HIV-1 subtype B and C strains isolated from the activated PBMCs of patients. M48U1 also inhibited infection by two HIV-1 transmitted/founder infectious molecular clones (pREJO.c/2864 and pTHRO.c/2626). In addition, M48U1 was administered in association with tenofovir, and these two antiretroviral drugs synergistically inhibited HIV-1 infection. In the next series of experiments, we tested M48U1 alone or in combination with tenofovir in HEC hydrogel with an organ-like structure mimicking human cervicovaginal tissue. We demonstrated a strong antiviral effect in absence of significant tissue toxicity. Together, these results indicate that co-Treatment with M48U1 plus tenofovir is an effective antiviral strategy that may be used as a new topical microbicide to prevent HIV-1 transmission. {\circledC} 2017 The Author(s).",
author = "G Musumeci and I Bon and D Lembo and V Cagno and MC Re and C Signoretto and E Diani and L Lopalco and C Pastori and L Martin and G Ponchel and D Gibellini and K Bouchemal",
year = "2017",
doi = "10.1038/srep41018",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures

AU - Musumeci, G

AU - Bon, I

AU - Lembo, D

AU - Cagno, V

AU - Re, MC

AU - Signoretto, C

AU - Diani, E

AU - Lopalco, L

AU - Pastori, C

AU - Martin, L

AU - Ponchel, G

AU - Gibellini, D

AU - Bouchemal, K

PY - 2017

Y1 - 2017

N2 - Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1) transmission and disease. In this report, we first analyzed the antiviral activity of the miniCD4 M48U1 peptide formulated in hydroxyethylcellulose (HEC) hydrogel in activated peripheral blood mononuclear cells (PBMCs) infected with R5-and X4-Tropic HIV-1 strains. The results demonstrate that M48U1 prevented infection by several HIV-1 strains including laboratory strains, and HIV-1 subtype B and C strains isolated from the activated PBMCs of patients. M48U1 also inhibited infection by two HIV-1 transmitted/founder infectious molecular clones (pREJO.c/2864 and pTHRO.c/2626). In addition, M48U1 was administered in association with tenofovir, and these two antiretroviral drugs synergistically inhibited HIV-1 infection. In the next series of experiments, we tested M48U1 alone or in combination with tenofovir in HEC hydrogel with an organ-like structure mimicking human cervicovaginal tissue. We demonstrated a strong antiviral effect in absence of significant tissue toxicity. Together, these results indicate that co-Treatment with M48U1 plus tenofovir is an effective antiviral strategy that may be used as a new topical microbicide to prevent HIV-1 transmission. © 2017 The Author(s).

AB - Microbicides are considered a promising strategy for preventing human immunodeficiency virus (HIV-1) transmission and disease. In this report, we first analyzed the antiviral activity of the miniCD4 M48U1 peptide formulated in hydroxyethylcellulose (HEC) hydrogel in activated peripheral blood mononuclear cells (PBMCs) infected with R5-and X4-Tropic HIV-1 strains. The results demonstrate that M48U1 prevented infection by several HIV-1 strains including laboratory strains, and HIV-1 subtype B and C strains isolated from the activated PBMCs of patients. M48U1 also inhibited infection by two HIV-1 transmitted/founder infectious molecular clones (pREJO.c/2864 and pTHRO.c/2626). In addition, M48U1 was administered in association with tenofovir, and these two antiretroviral drugs synergistically inhibited HIV-1 infection. In the next series of experiments, we tested M48U1 alone or in combination with tenofovir in HEC hydrogel with an organ-like structure mimicking human cervicovaginal tissue. We demonstrated a strong antiviral effect in absence of significant tissue toxicity. Together, these results indicate that co-Treatment with M48U1 plus tenofovir is an effective antiviral strategy that may be used as a new topical microbicide to prevent HIV-1 transmission. © 2017 The Author(s).

U2 - 10.1038/srep41018

DO - 10.1038/srep41018

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 10

M1 - 41018

ER -